Search Results - "Wong, V W S"

Laboratory parameter‐based machine learning model for excluding non‐alcoholic fatty liver disease (NAFLD) in the general population by Yip, T. C.‐F., Ma, A. J., Wong, V. W.‐S., Tse, Y.‐K., Chan, H. L.‐Y., Yuen, P.‐C., Wong, G. L.‐H.

“…Summary Background Non‐alcoholic fatty liver disease (NAFLD) affects 20%‐40% of the general population in developed countries and is an increasingly important…”
Get full text

Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments by Kwok, R., Tse, Y.‐K., Wong, G. L.‐H., Ha, Y., Lee, A. U., Ngu, M. C., Chan, H. L.‐Y., Wong, V. W.‐S.

“…Summary Background Non‐alcoholic fatty liver disease (NAFLD) affects 15–40% of the general population. Some patients have non‐alcoholic steatohepatitis (NASH)…”
Get full text

Review article: long‐term safety of oral anti‐viral treatment for chronic hepatitis B by Wong, G. L.‐H., Seto, W.‐K., Wong, V. W.‐S., Yuen, M.‐F., Chan, H. L.‐Y.

“…Summary Background Safety profile of nucleos(t)ide analogues is an important issue in view of its widespread use for decades in patients with chronic hepatitis…”
Get full text

Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD by Petta, S., Wong, V. W.‐S., Cammà, C., Hiriart, J.‐B., Wong, G. L.‐H., Vergniol, J., Chan, A. W.‐H., Di Marco, V., Merrouche, W., Chan, H. L.‐Y., Marra, F., Le‐Bail, B., Arena, U., Craxì, A., Ledinghen, V.

“…Summary Background The accuracy of available non‐invasive tools for staging severe fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) is still…”
Get full text

Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B by Chan, H. L.-Y., Wong, G. L.-H., Choi, P. C.-L., Chan, A. W.-H., Chim, A. M.-L., Yiu, K. K.-L., Chan, F. K.-L., Sung, J. J.-Y., Wong, V. W.-S.

“…The aim of this study is to know the liver stiffness measurement (LSM) cutoffs for different stages of liver fibrosis in chronic hepatitis B (CHB) and to…”
Get full text

PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome by Shen, J., Wong, G. L.‐H., Chan, H. L.‐Y., Chan, H.‐Y., Yeung, D. K.‐W., Chan, R. S.‐M., Chim, A. M.‐L., Chan, A. W.‐H., Choi, P. C.‐L., Woo, J., Chu, W. C.‐W., Wong, V. W.‐S.

“…Summary Background The rs738409 GG variant in patatin‐like phospholipase 3 (PNPLA3) is associated with non‐alcoholic fatty liver disease (NAFLD) and disease…”
Get full text

Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region—the GO ASIA initiative by Chan, W.‐K., Treeprasertsuk, S., Imajo, K., Nakajima, A., Seki, Y., Kasama, K., Kakizaki, S., Fan, J.‐G., Song, M. J., Yoon, S. K., Dan, Y.‐Y., Lesmana, L., Ho, K.‐Y., Goh, K.‐L., Wong, V. W.‐S.

“…Summary Background The Gut and Obesity Asia (GO ASIA) workgroup was formed to study the relationships between obesity and gastrointestinal diseases in the Asia…”
Get full text

Predictors of relapse in chronic hepatitis B after discontinuation of anti‐viral therapy by Liang, Y., Jiang, J., Su, M., Liu, Z., Guo, W., Huang, X., Xie, R., Ge, S., Hu, J., Jiang, Z., Zhu, M., Wong, V. W.‐S., Chan, H. L.‐Y.

“…Aliment Pharmacol Ther 2011; 34: 344–352 Summary Background  Optimal duration of anti‐viral therapy in chronic hepatitis B virus (HBV) infection remains…”
Get full text

Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma by SUNG, J. J. Y., TSOI, K. K. F., WONG, V. W. S., LI, K. C. T., CHAN, H. L. Y.

“…Summary Background  Chronic hepatitis B (CHB) infection leads to development of hepatocellular carcinoma (HCC), but the effects of treatment in preventing HCC…”
Get full text

Significant positive association of endotoxemia with histological severity in 237 patients with non‐alcoholic fatty liver disease by Pang, J., Xu, W., Zhang, X., Wong, G. L.‐H., Chan, A. W.‐H., Chan, H.‐Y., Tse, C.‐H., Shu, S. S.‐T., Choi, P. C.‐L., Chan, H. L.‐Y., Yu, J., Wong, V. W.‐S.

“…Summary Background Patients with nonalcoholic steatohepatitis (NASH) have gut dysbiosis and intestinal bacterial overgrowth. Aim To test the hypothesis that…”
Get full text

Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis by Wong, J. C.‐T., Chan, H. L.‐Y., Tse, Y.‐K., Yip, T. C.‐F., Wong, V. W.‐S., Wong, G. L.‐H.

“…Summary Background Decompensated liver disease due to portal hypertension leads to significant morbidity and mortality. Statins can modulate intrahepatic…”
Get full text

Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations by Wong, G. L.‐H., Chan, H. L.‐Y., Yu, Z., Chan, A. W.‐H., Choi, P. C.‐L., Chim, A. M.‐L., Chan, H.‐Y., Tse, C.‐H., Wong, V. W.‐S.

“…Summary Background Metabolic syndrome is a known risk factor of cirrhosis in chronic hepatitis B (CHB). Aim To investigate the effects of coincidental…”
Get full text

Meta‐analysis: the efficacy of anti‐viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B‐related hepatocellular carcinoma by Wong, J. S.‐W., Wong, G. L.‐H., Tsoi, K. K.‐F., Wong, V. W.‐S., Cheung, S. Y.‐S., Chong, C.‐N., Wong, J., Lee, K.‐F., Lai, P. B.‐S., Chan, H. L.‐Y.

“…Aliment Pharmacol Ther 2011; 33: 1104–1112 Summary Background  The role of anti‐viral therapy in prevention of hepatocellular carcinoma (HCC) recurrence is to…”
Get full text

Meta‐analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma by Wong, G. L.‐H., Chan, H. L.‐Y., Yiu, K. K.‐L., Lai, J. W.‐Y., Chan, V. K.‐K., Cheung, K. K.‐C., Wong, E. W.‐N., Wong, V. W.‐S.

“…Summary Background A meta‐analysis on the risk of hepatocellular carcinoma (HCC) among hepatitis B virus (HBV) genotypes is warranted as the current data are…”
Get full text

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B by Chan, H. L.‐Y., Wong, V. W.‐S., Chim, A. M.‐L., Chan, H.‐Y., Wong, G. L.‐H., Sung, J. J.‐Y.

“…Aliment Pharmacol Ther 2010; 32: 1323–1331 Summary Background  On‐treatment predictors of response to peginterferon can guide individualization of therapy in…”
Get full text

Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B‐related hepatocellular carcinoma by Wong, G. L.‐H., Tse, Y.‐K., Chan, H. L.‐Y., Yip, T. C.‐F., Tsoi, K. K.‐F., Wong, V. W.‐S.

“…Summary Background In patients with chronic hepatitis B (CHB)‐related hepatocellular carcinoma (HCC), high viral load was associated with tumour recurrence and…”
Get full text

Non‐invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B by Wong, G. L.‐H., Chan, H. L.‐Y., Choi, P. C.‐L., Chan, A. W.‐H., Yu, Z., Lai, J. W.‐Y., Chan, H.‐Y., Wong, V. W.‐S.

“…Summary Background The accuracy of Enhanced Liver Fibrosis (ELF; ADVIA Centaur, Siemens Healthcare Diagnostics, Tarrytown, NY, USA) in assessing liver fibrosis…”
Get full text

Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B by Wong, G L-H, Wong, V W-S, Choi, P C-L, Chan, A W-H, Chim, A M-L, Yiu, K K-L, Chan, H-Y, Chan, F K-L, Sung, J J-Y, Chan, H L-Y

“…Metabolic syndrome is associated with non-alcoholic steatohepatitis and cryptogenic cirrhosis. Whether metabolic syndrome affects the severity of chronic…”
Get more information

Long‐term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk – a cohort study of 44 494 subjects by Wong, G. L.‐H., Tse, Y.‐K., Yip, T. C.‐F., Chan, H. L.‐Y., Tsoi, K. K.‐F., Wong, V. W.‐S.

“…Summary Background Patients with chronic hepatitis B (CHB) need long‐term antiviral treatment with nucleos(t)ide analogues (NA). Animal studies suggest that…”
Get full text

Bacterial endotoxin and non‐alcoholic fatty liver disease in the general population: a prospective cohort study by Wong, V. W.‐S., Wong, G. L.‐H., Chan, H.‐Y., Yeung, D. K.‐W., Chan, R. S.‐M., Chim, A. M.‐L., Chan, C. K.‐M., Tse, Y.‐K., Woo, J., Chu, W. C.‐W., Chan, H. L.‐Y.

“…Summary Background Patients with non‐alcoholic steatohepatitis (NASH) have increased intestinal permeability and small intestine bacterial overgrowth. Aims To…”
Get full text